SES
11.5.2023 08:51:31 CEST | Business Wire | Press release
EAGLE-1 consortium lead SES announces a new key partner, TESAT, responsible for developing and integrating the Quantum Key Distribution (QKD) payload for the EAGLE-1 satellite. The SES and TESAT partnership is aimed at achieving the next key milestone in building and implementing Europe’s pioneering quantum secure communications initiative EAGLE-1. Supported by the European Space Agency (ESA) and the European Commission, EAGLE-1 is a quantum key system integrating both space and ground segments that will deliver secure transmission of encryption keys across geographically dispersed areas and connect EU’s national quantum communications infrastructures for truly sovereign networks.
Consortium member and Europe’s leading laser communication technology company TESAT will manufacture the QKD payload comprising the Scalable Optical Terminal SCOT80 to establish a secure optical link from space to ground, as well as the QKD module of the satellite.
The technology integrated into the EAGLE-1 system’s payload will include built-in redundancy and is specifically designed to be associated with the satellite communications and data transmission for such areas as government, telco operators, cloud providers and banking, to add guaranteed security of the cryptographic applications.
“EAGLE-1 is a project that will benefit the whole of Europe, and being able to work with the leading technology players in the market to co-develop it and together shape this innovative secure technology is a privilege to SES,” said Ruy Pinto, Chief technology Officer of SES. “The addition of the secure optical links and the actual QKD module brings us closer to implementation, testing and further scaling the technology, that can ultimately serve millions of users. This elevates secure communications to an entirely new level, supporting development of reliable pan-European quantum communications infrastructures.”
“We are delighted to be selected as payload prime by SES and looking forward to bring our expertise in integrating secure technologies, and a track record of almost 80,000 executed optical satellite links for the benefit of this highly-important and timely European project,” said Thomas Reinartz, CEO of TESAT. “The EAGLE-1 system allows for achieving synergies together with leading industry partners, SMEs and institutes, reducing time to service and to market for the quantum secure technologies and its future key users, such as governments and institutions, or banking sector. Together with our partners, we are looking forward to strengthen European collaboration at all levels, including SMEs and institutions and contributing to European sovereignty in space.”
About EAGLE-1
The EAGLE-1 project comprising satellite and ground infrastructure is developed by SES and its consortium of 20 European partners, and is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.
Once launched in 2024, the EAGLE-1 satellite will complete three years of in-orbit mission. During the operational phase, the satellite will allow European Union governments and institutions as well as critical business sectors early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.
Learn more about EAGLE-1 and SES-led consortium of European partners here.
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 369 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About TESAT
TESAT is a world-leading manufacturer for satellite equipment. More than 1,100 employees, based in Backnang, Germany, develop, manufacture and distribute systems and equipment for satellite communications every day. The product range spans from the smallest space-specific components to modules, entire assemblies or payloads. As the world’s leading provider of in-orbit-verified optical communication terminals for data transmission via laser, TESAT has a focus on commercial and institutional space programs. Thanks to the deep understanding of the market needs, customer focus and technological innovation, TESAT offers products that contribute to sustainable development and security, for the people, for a better world. More information at www.tesat.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom